Stora Enso acquires Swedish cellulose technology company
Stora Enso has increased its ownership up to 100% in the Sweden-based company Cellutech AB. The company specialises in the development of new materials and applications based on cellulose, micro-fibrillated cellulose (MFC) and other wood-based components.
The acquisition of Cellutech supports Stora Enso’s vision of replacing fossil-based materials with renewable ones originating from wood. The acquired company works, among others, in the areas of foams for packaging and hydroponics where the markets are continuously growing. Cellulosic foams can, for example, be used in packaging to replace polystyrenes which are the most widely used plastics.
“The acquisition of Cellutech will add a new dimension to our fibre and cellulose capabilities particularly in lightweight cellulose foams and spheres. We are investing in technologies and expertise that will further broaden application development competence in Stora Enso’s biomaterials Division,” says Markus Mannström, EVP, Stora Enso Biomaterials.
Established in 2013, Cellutech is an agile team of eight scientists and researchers serving as a link between academia and industry. Cellutech was formed to take world class scientific research developed at SweTree Technologies and Wallenberg Wood Science Center and develop the ideas into commercially successful technologies and products.
The transaction will not have a material financial impact on the Group.
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Researchers dramatically downsize technology for fingerprinting drugs and other chemicals - Tiny photonic chip could fit comfortably within the tip of a finger

Biopreservation Solutions | Cell culture reagents | Sartorius
UC San Diego Skaggs School of Pharmacy and Janssen R&D collaborate to treat Chagas disease - Team will seek new therapeutic targets and treatments for this neglected tropical disease

Could new cancer drugs come from potatoes and tomatoes? - Future cancer drugs may one day be formulated from glycoalkaloids found in plants from the genus Solanum
OGT Presents Promising Prostate Cancer Biomarker Panel Results - Company optimistic about pilot data and embarks on rigorous clinical study
Final report: analytica China 2010 strengthens leading position on Chinese market
CytomX and MD Anderson Cancer Center enter collaboration for Probody-enabled CAR-NK cell therapies

Stressed-out rats consume more alcohol, revealing related brain chemistry
Twelve outstanding young scientists named as EMBO Young Investigators

New study sheds light on genetics of rice metabolism
